© AzurPharma Ltd.
Company Number 399192
45 Fitzwilliam Square
Dublin 2
Ireland.
1818 Market Street
Suite 2350
Philadelphia
PA 19103
USA.
Azur Pharma is a private pharmaceutical company focused on the CNS, women’s health and urology markets of the US. The company is headquartered in Dublin, Ireland.
Azur Pharma markets a portfolio of prescription products through its US national sales infrastructure consisting of close to 100 sales representatives made up of 50 specialty CNS representatives with the remainder women’s health / urology representatives. Azur Pharma's portfolio comprises FazaClo®, Gastrocrom®, women's health products and urology products. FazaClo is an antipsychotic drug indicated for the management of severely ill schizophrenic patients who fail to respond to standard treatments. FazaClo also is indicated for reduction in the risk of recurrent suicidal behaviour in schizophrenia or schizoaffective disorders. Gastrocrom is indicated for the management of patients with mastocytosis. The remaining products are focussed in the prenatal vitamin and urology areas.
Azur Pharma’s mission is to build an integrated pharmaceutical company focussed on the areas of CNS, women’s health and urology. Azur Pharma’s strategy is to acquire marketed products and late stage development opportunities in our target markets to leverage the specialist sales forces we have developed for these markets.
The company was founded in May 2005 with a private equity funding of €40 million ($60 million). Since that time, Azur Pharma has acquired Gastrocrom from UCB Pharma, Pharmelle a women's health and urology business, and FazaClo from Avanir Pharmaceuticals. Azur Pharma also completed an additional €35 million ($50 million) equity financing in August 2007.
We invite you to explore our web site and learn more about Azur Pharma.